These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and feasibility of ruxolitinib in chronic steroid-refractory GVHD in a pediatric intestine transplant. Ghobrial S; Gonzalez C; Yazigi N; Kaufman S; Matsumoto C; Fishbein T; Hawksworth J; Kroemer A; Khan K Pediatr Transplant; 2021 May; 25(3):e13836. PubMed ID: 32981124 [TBL] [Abstract][Full Text] [Related]
33. Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma. Lythgoe H; Baildam E; Beresford MW; Cleary G; McCann LJ; Pain CE Rheumatology (Oxford); 2018 Feb; 57(2):398-401. PubMed ID: 29077971 [No Abstract] [Full Text] [Related]
34. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease. Kim JB; Liakopoulou E; Watson JS J Plast Reconstr Aesthet Surg; 2008 Oct; 61(10):1235-8. PubMed ID: 17509955 [TBL] [Abstract][Full Text] [Related]
35. Ruxolitinib as a promising treatment for corticosteroid-refractory graft-versus-host disease. Assouan D; Lebon D; Charbonnier A; Royer B; Marolleau JP; Gruson B Br J Haematol; 2018 Jun; 181(5):687-689. PubMed ID: 28444730 [No Abstract] [Full Text] [Related]
36. A call for more dermatologic input into chronic graft-vs-host disease clinical trials. Cowen EW Arch Dermatol; 2009 Mar; 145(3):337-8. PubMed ID: 19289778 [No Abstract] [Full Text] [Related]
37. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484 [TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. Uygun V; Karasu G; Daloğlu H; Öztürkmen S; Kılıç SÇ; Yalçın K; Çelen SS; Hazar V; Yeşilipek A Pediatr Blood Cancer; 2020 Apr; 67(4):e28190. PubMed ID: 31981413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]